檢索結果 - Peter Weisenseel
- Showing 1 - 3 results of 3
-
1
IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants... 由 Kilian Eyerich, Peter Weisenseel, Andreas Pinter, Knut Schäkel, Khusru Asadullah, Sven Wegner, Ernesto J. Muñoz‐Elías, Holger Bartz, F. Taut, Kristian Reich
出版 2021Artigo -
2
Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance (‘clinical super response’): Week 28 results from the ongoing phase... 由 Knut Schäkel, Kristian Reich, K. Asadullah, Andreas Pinter, D. Jullien, Peter Weisenseel, C. Paul, Mario Gomez, Sven Wegner, Yvonne Personke, Fabian Kreimendahl, Yanqing Chen, Julianty Angsana, Monica Leung, Kilian Eyerich
出版 2023Artigo -
3
Noninferiority of 16-Week vs 8-Week Guselkumab Dosing in Super Responders for Maintaining Control of Psoriasis 由 Kilian Eyerich, Khusru Asadullah, Andreas Pinter, Peter Weisenseel, Kristian Reich, C. Paul, Robert Sabat, Kerstin Wolk, Stefanie Eyerich, Felix Lauffer, Julianty Angsana, Friedemann Taut, Kristen Kohler, Yanqing Chen, Jocelyn Sendecki, Monica Leung, Sven Wegner, Yvonne Personke, Mario Gomez, Nenja Krüger, Sarah Tabori, Knut Schäkel
出版 2024Carta
相關主題
Dermatology
Internal medicine
Medicine
Psoriasis
Clinical trial
Alternative medicine
Biochemistry
Biomarker
Blockade
Chemistry
Disease
Dosing
Double blind
Double blind study
Gastroenterology
Logistic regression
Pathogenesis
Pathology
Placebo
Plaque psoriasis
Psoriasis Area and Severity Index
Randomized controlled trial
Receptor